Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 9/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26914700 | 0.88 | CYP2D6 (0.50) | MCHR1HRH3ESR1L3MBTL1MEN1 | |
| SCHEMBL30615777 | 0.77 | MEN1 (0.65) | MCHR1HRH3ESR1KDRL3MBTL1 | |
| SCHEMBL6516191 | 0.69 | POLB (0.54) | POLBALOX15L3MBTL1MEN1KMT2A | |
| SCHEMBL12440415 | 0.68 | MCHR1 (0.73) | MCHR1ESR1KDRHSD17B10 | |
| SCHEMBL19642909 | 0.68 | MCHR1 (0.59) | MCHR1HRH3CYP1A2LTA4HCYP2D6 | |
| SCHEMBL6521129 | 0.68 | CXCR2 (0.49) | POLBRXFP1ALOX15L3MBTL1MEN1 | |
| SCHEMBL11037574 | 0.67 | MAPKAPK2 (0.61) | MCHR1ESR1 | |
| SCHEMBL12440250 | 0.67 | MCHR1 (0.68) | MCHR1ESR1KDR | |
| SCHEMBL9706125 | 0.67 | EBP (0.72) | MCHR1HRH3ESR1KMT2ACYP1A2 | |
| SCHEMBL29926942 | 0.67 | CYP19A1 (0.52) | MCHR1KDRMEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025146850-A1 | METHOD FOR PREPARING NOVEL COMPOUND | (주)피알지에스앤텍 | 2025-07-10 | — | — | WO | disclosed |
| US-20240092741-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF NEUROFIBROMATOSIS TYPE 2 SYNDROME | PRG S&TECH INC. (KR) | 2024-03-21 | — | — | US | disclosed |
| EP-4289825-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF NEUROFIBROMATOSIS TYPE 2 SYNDROME | PRG S&Tech Inc. (KR) | 2023-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092741-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF NEUROFIBROMATOSIS TYPE 2 SYNDROME | TGFBR2, TGFBR1, TGFB2 | MCHR1 2213/4885HRH3 2402/4885POLB 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.